Dyadic International (DYAI)

$1.50 +0.01 (0.67%)
Market Cap 44.38M
Revenue (ttm) 2.90M
Net Income (ttm) -6.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -234.48%
Debt to Equity Ratio 0.00
Volume 24,500
Avg Vol 120,080
Day's Range N/A - N/A
Shares Out 29.59M
Stochastic %K 7%
Beta 0.89
Analysts Strong Sell
Price Target $7.50

Latest News on DYAI

Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 8:30 AM EST - 12 days ago

Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference

Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology

Nov 21, 2024, 8:30 AM EST - 2 months ago

Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology

Dyadic International, Inc. (DYAI) Q3 2024 Earnings Call Transcript

Nov 16, 2024, 8:16 PM EST - 2 months ago

Dyadic International, Inc. (DYAI) Q3 2024 Earnings Call Transcript

Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Nov 4, 2024, 4:30 PM EST - 2 months ago

Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Dyadic Expands Global Presence with Participation in Key Industry Events

Oct 9, 2024, 8:00 AM EDT - 3 months ago

Dyadic Expands Global Presence with Participation in Key Industry Events

Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference

Sep 23, 2024, 9:50 AM EDT - 4 months ago

Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference

Dyadic International, Inc. (DYAI) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 11:05 PM EDT - 5 months ago

Dyadic International, Inc. (DYAI) Q2 2024 Earnings Call Transcript

Dyadic to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024

Jul 30, 2024, 4:00 PM EDT - 6 months ago

Dyadic to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024

Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership

Jun 28, 2024, 8:30 AM EDT - 7 months ago

Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership

Dyadic to Attend Industry Events in June

May 30, 2024, 4:30 PM EDT - 8 months ago

Dyadic to Attend Industry Events in June

Dyadic International, Inc. (DYAI) Q1 2024 Earnings Call Transcript

May 17, 2024, 10:15 PM EDT - 8 months ago

Dyadic International, Inc. (DYAI) Q1 2024 Earnings Call Transcript

Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

May 14, 2024, 4:00 PM EDT - 8 months ago

Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

Dyadic to Attend Industry and Investor Events in May

May 8, 2024, 8:30 AM EDT - 9 months ago

Dyadic to Attend Industry and Investor Events in May

Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024

Apr 30, 2024, 4:30 PM EDT - 9 months ago

Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024

Dyadic International, Inc. (DYAI) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 10:22 PM EDT - 10 months ago

Dyadic International, Inc. (DYAI) Q4 2023 Earnings Call Transcript

Dyadic Reports 2023 Full Year Results and Recent Company Progress

Mar 28, 2024, 4:00 PM EDT - 10 months ago

Dyadic Reports 2023 Full Year Results and Recent Company Progress

Dyadic Announces Change in Board and Management Leadership Roles

Mar 28, 2024, 8:30 AM EDT - 10 months ago

Dyadic Announces Change in Board and Management Leadership Roles

Dyadic to Attend Industry Events in April

Mar 27, 2024, 8:30 AM EDT - 10 months ago

Dyadic to Attend Industry Events in April

Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications

Mar 26, 2024, 8:30 AM EDT - 10 months ago

Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications

Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California

Mar 21, 2024, 8:30 AM EDT - 10 months ago

Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California

Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024

Mar 14, 2024, 4:30 PM EDT - 11 months ago

Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024

CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization

Mar 11, 2024, 9:57 AM EDT - 11 months ago

CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization

Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization

Mar 11, 2024, 8:30 AM EDT - 11 months ago

Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization

Dyadic to Attend Industry Events in March

Mar 1, 2024, 8:30 AM EST - 11 months ago

Dyadic to Attend Industry Events in March

Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform

Feb 28, 2024, 8:30 AM EST - 11 months ago

Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

Feb 23, 2024, 2:00 AM EST - 11 months ago

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

Feb 21, 2024, 8:30 AM EST - 11 months ago

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing

Feb 13, 2024, 8:30 AM EST - 1 year ago

Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing

Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company

Feb 6, 2024, 8:30 AM EST - 1 year ago

Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company

Dyadic to Attend BIO CEO & Investor Conference and European Industry Events

Feb 1, 2024, 8:30 AM EST - 1 year ago

Dyadic to Attend BIO CEO & Investor Conference and European Industry Events

Dyadic International, Inc Invites You to Join Us at The Microcap Conference

Jan 22, 2024, 8:00 AM EST - 1 year ago

Dyadic International, Inc Invites You to Join Us at The Microcap Conference

Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference

Jan 2, 2024, 8:30 AM EST - 1 year ago

Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference

Dyadic Attends Investor Events in December

Nov 30, 2023, 8:30 AM EST - 1 year ago

Dyadic Attends Investor Events in December

Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate

Nov 29, 2023, 8:30 AM EST - 1 year ago

Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate

Dyadic's C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa

Nov 20, 2023, 8:30 AM EST - 1 year ago

Dyadic's C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa

Dyadic International, Inc. (DYAI) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 11:23 PM EST - 1 year ago

Dyadic International, Inc. (DYAI) Q3 2023 Earnings Call Transcript

Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Nov 8, 2023, 4:00 PM EST - 1 year ago

Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Dyadic to Present at Industry Events in November

Oct 30, 2023, 8:30 AM EDT - 1 year ago

Dyadic to Present at Industry Events in November

Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

Oct 25, 2023, 4:30 PM EDT - 1 year ago

Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

Dyadic Appoints Doug Pace to Its Executive Leadership Team

Oct 9, 2023, 8:30 AM EDT - 1 year ago

Dyadic Appoints Doug Pace to Its Executive Leadership Team

Dyadic's C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC's $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vacci

Oct 5, 2023, 8:30 AM EDT - 1 year ago

Dyadic's C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC's $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vacci

Dyadic to Present at Industry and Investor Events in October

Sep 29, 2023, 8:30 AM EDT - 1 year ago

Dyadic to Present at Industry and Investor Events in October

Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells

Sep 26, 2023, 8:30 AM EDT - 1 year ago

Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells

Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™

Sep 19, 2023, 8:00 AM EDT - 1 year ago

Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™

Dyadic to Present at BioProcess International

Sep 12, 2023, 4:30 PM EDT - 1 year ago

Dyadic to Present at BioProcess International

Dyadic International, Inc. (DYAI) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 11:41 PM EDT - 1 year ago

Dyadic International, Inc. (DYAI) Q2 2023 Earnings Call Transcript

Dyadic Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Aug 9, 2023, 4:00 PM EDT - 1 year ago

Dyadic Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin

Aug 7, 2023, 8:30 AM EDT - 1 year ago

Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin

Dyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023

Jul 26, 2023, 4:30 PM EDT - 1 year ago

Dyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023

Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate

Jul 24, 2023, 8:30 AM EDT - 1 year ago

Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate